Investment News

6h

MaxCyte Signs Akron BioProducts Acquisition Agreement as Stereotaxis Secures Up to $24 Million in Convertible Financing

  • MaxCyte agrees to acquire Akron BioProducts while Stereotaxis arranges up to $24 million in convertible notes for medical-technology expansion.
CTA-image

Market Movers (Top 10)
Last Updated:
Market Movers (Bottom 10)
Last Updated: